Focused R&D and Faster, Lower-Risk Development Through Partnerships

「承認取得後はＩｔａｌｆａｒｍａｃｏが対象地域で販売と流通を担い、同社は製造を継続する。」

「本契約は、希少疾病および遺伝性疾患の治療薬開発に対する Italfarmaco とのパートナーシップへの当社の取り組みをさらに広げるものです。」

「In December 2025, we entered into an agreement for a strategic partnership with Italfarmaco concerning treatments for rare diseases. Through this agreement, we aim to expand both companies’ portfolios and explore opportunities for collaboration in our R&D pipeline and foundational technologies.」

「The company began joint research with MODALIS in December 2023 to develop a novel gene therapy using this technology. In January 2025, it concluded a new joint research agreement after achieving validation of the initial technical concept in the joint research.」

「We are actively pursuing alliances based on this proprietary technology. In March 2023, we entered into a research and development agreement with Alexion for the application of J-Brain Cargo® to a protein in a drug candidate for neurodegenerative diseases, and in December of the same year we entered into a licence agreement for the creation of nucleic acid pharmaceuticals for rare diseases. Research has progressed smoothly, and in March 2024 we achieved the first milestone for a treatment for neurodegenerative diseases.」

「In December 2023, we entered into a joint research, option and licence agreement with Alexion, AstraZeneca Rare Disease (Alexion) for the creation of novel nucleic acid pharmaceuticals using the J-Brain Cargo® technology.」

「In May 2023, the company concluded an exclusive global development and commercialization agreement with Angelini Pharma for a novel biologic applying J-Brain Cargo® technology to epilepsy.」

「We will pursue the creation of innovative pharmaceuticals while taking advantage of opportunities for alliances with other companies in parallel with our own research and development activities. In March 2023, we achieved preclinical proof of concept under the joint research and development agreement with 武田薬品工業株式会社 for gene therapy using the J-Brain Cargo® technology for lysosomal diseases.」

「In addition to the above, in March 2022 we entered into a joint research and development agreement with 武田薬品工業株式会社 for gene therapies using the J-Brain Cargo® technology for multiple lysosomal diseases.」

「In September 2021, we entered into an agreement with 武田薬品工業株式会社 for the joint development and commercialisation of JR-141, a next-generation treatment for Hunter syndrome, in certain regions.」

「In the pharmaceutical industry, it takes more than 10 years, including basic research, for a new platform technology to be developed into a pharmaceutical product. We expect development of the series of lysosomal disease treatments, our highest priority, to be substantially completed over the next 10 years or so. Accordingly, we will strengthen our basic research efforts to create new platform technologies for the period beyond development of lysosomal disease treatments.」

「The company began selling darbepoetin alfa BS injection "JCR," a long-acting erythropoiesis-stimulating agent jointly developed with キッセイ薬品工業株式会社, in November last year following receipt of marketing approval, and recorded sales of ¥649 million.」

「On 20 September, the Company obtained marketing approval for the long-acting erythropoiesis-stimulating agent darbepoetin alfa BS injection 「JCR」, jointly developed with キッセイ薬品工業株式会社.」

「In September last year, the company filed an application for marketing approval of the biosimilar of the long-acting erythropoiesis-stimulating agent darbepoetin alfa (development code: JR-131), which is being jointly developed with キッセイ薬品工業株式会社.」

「The company filed an application for marketing approval of the biosimilar of the long-acting erythropoiesis-stimulating agent darbepoetin alfa (development code: JR-131) in September last year, and an application for marketing approval of the regenerative medicine product "Temcell® HS Inj." for an expanded indication in epidermolysis bullosa (development code: JR-031EB) in March this year.」

「On 28 September this year, the company filed an application for marketing approval of the biosimilar of the long-acting erythropoiesis-stimulating agent darbepoetin alfa (development code: JR-131), which is being jointly developed with キッセイ薬品工業株式会社.」

「In other therapeutic areas, the biosimilar of the long-acting erythropoiesis-stimulating agent darbepoetin alfa (development code: JR-131), jointly developed with キッセイ薬品工業株式会社, is under preparation for a marketing approval application and is progressing as scheduled. In the cell and regenerative medicine field, the company entered into a joint development agreement and a licensing agreement with 帝人株式会社 in July last year for a regenerative medicine product using allogeneic dental pulp-derived stem cells (DPC) for the treatment of acute ischemic stroke (development code: JTR-161), and is advancing research and development.」

「In February this year, favorable results from joint research on J-Brain Cargo® with 大日本住友製薬株式会社 led to the development of a licensing agreement. In the cell and regenerative medicine field, the company entered into a joint development agreement and a licensing agreement with 帝人株式会社 in July last year for a regenerative medicine product using allogeneic dental pulp-derived stem cells (DPC) for the treatment of acute ischemic stroke (development code: JTR-161), and is advancing development jointly.」

「On 18 July of this year, the company concluded a joint development agreement and license agreement with Teijin Limited for a regenerative medical product for acute ischemic stroke using allogeneic (homologous) dental pulp-derived stem cells (DPC) (development code: JTR-161).」

「As part of its licensing business, the company pursued negotiations with Teijin Limited to conclude a joint development agreement and license agreement for a regenerative medical product for acute ischemic stroke using allogeneic (homologous) dental pulp-derived stem cells (DPC) (development code: JTR-161).」

「Joint development of JR-131, a biosimilar of darbepoetin alfa, with キッセイ薬品工業㈱」

「Amid this active research and development, in July last year the company entered into a new development investment agreement with メディパルホールディングス covering 2 products currently under research and development by the company.」

「In July this year, the company entered into a new development investment agreement with メディパルホールディングス covering 2 products currently under research and development by the company.」

「In response to these factors, the group intends to enhance its product lineup and stabilize and improve earnings by pursuing the following basic policies: ① further increasing the added value and sales capabilities of core products, ② accelerating new drug development and reducing risk through partnerships with other companies, and ③ narrowing the focus of key research and development themes.」